647 related articles for article (PubMed ID: 19651512)
1. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
[TBL] [Abstract][Full Text] [Related]
2. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
Landesberg R; Wilson T; Grbic JT
Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
9. [A case of osteonecrosis of the lower jaw due to bisphosphonates in a breast cancer patient with bone metastasis].
Kubo N; Katayama K; Ishizaki A; Morinaga N; Negishi T; Kuwano H
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1973-5. PubMed ID: 19011355
[TBL] [Abstract][Full Text] [Related]
10. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
Van Poznak C
Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
[TBL] [Abstract][Full Text] [Related]
12. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
13. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and osteonecrosis of the jaw.
Sambrook P; Olver I; Goss A
Aust Fam Physician; 2006 Oct; 35(10):801-3. PubMed ID: 17019456
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Diel IJ; Fogelman I; Al-Nawas B; Hoffmeister B; Migliorati C; Gligorov J; Väänänen K; Pylkkänen L; Pecherstorfer M; Aapro MS
Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S
J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158
[TBL] [Abstract][Full Text] [Related]
19. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
Dodson TB
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
[TBL] [Abstract][Full Text] [Related]
20. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
